1. Home
  2. Live Updates
  3. Sao paulo hcor research institute

Live Breaking News & Updates on Sao Paulo Hcor Research Institute

Stay updated with breaking news from Sao paulo hcor research institute. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Chinese firm's COVID-19 drug claims draw scientists' skepticism | WSAU News/Talk 550 AM · 99.9 FM


Chinese firm’s COVID-19 drug claims draw scientists’ skepticism
By Syndicated Content
By Gabriel Stargardter
(Reuters) – Chinese biotech firm Kintor Pharmaceutical Limited [9939.HK] saw its stock price jump by more than 20% the day after it announced on April 25 that it had “completed the first patient enrollment and dosing” in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.
It was the company’s latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed company’s stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalization soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($850 million) on March 1. ....

United States , Hong Kong , Brian Thevenot , Michele Gershberg , Alexandre Cavalcanti , Ricardo Zimerman , Gabriel Stargardter , Carlos Wambier , Lucy Lu , Zeid Kayali , Jair Bolsonaro , Stephen Ostroff , International In Hong Kong , Sao Paulo Hcor Research Institute , Drug Administration , Kintor Pharmaceutical , Brazilian Health Ministry , Brazil Health Ministry , Brown University , Kintor Pharmaceutical Limited , Hong Kong Listed , Sao Paulo , Research Institute , Chief Executive Tong Youzhi , China Renaissance , President Jair ,

Scientists skeptical over Chinese firm's Covid-19 drug claims, firm's stocks surge


Scientists skeptical over Chinese firm s Covid-19 drug claims, firm s stocks surge
Reuters
Chinese Covid drug
Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had completed the first patient enrollment and dosing in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.
It was the company s latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed company s stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalization soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($850 million) on March 1. ....

United States , Hong Kong , Lucy Lu , Alexandre Cavalcanti , Ricardo Zimerman , Zeid Kayali , Carlos Wambier , Stephen Ostroff , Jair Bolsonaro , International In Hong Kong , Sao Paulo Hcor Research Institute , Drug Administration , Kintor Pharmaceutical , Brazilian Health Ministry , Brazil Health Ministry , Brown University , Chinese Covid , Kintor Pharmaceutical Limited , Hong Kong Listed , Sao Paulo , Research Institute , Chief Executive Tong Youzhi , China Renaissance , President Jair , Helio Angotti , Brazilian Proxalutamide ,

Chinese firm's COVID-19 drug claims draw skepticism

Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had "completed the first patient enrollment and dosing" in a late-stage U.S. clinical trial of its experimental COVID-19 treatment. ....

United States , Hong Kong , Brian Thevenot , Michele Gershberg , Donny Kwok , Alexandre Cavalcanti , Ricardo Zimerman , Gabriel Stargardter , Carlos Wambier , Lucy Lu , Zeid Kayali , Jair Bolsonaro , Stephen Ostroff , Thomson Reuters Trust Principles , International In Hong Kong , Sao Paulo Hcor Research Institute , Drug Administration , Kintor Pharmaceutical , Brazilian Health Ministry , Brazil Health Ministry , Brown University , Kintor Pharmaceutical Limited , Hong Kong Listed , Sao Paulo , Research Institute , Chief Executive Tong Youzhi ,

Chinese firm's COVID-19 drug claims draw scientists' ...


By Gabriel Stargardter
May 14 (Reuters) - Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had completed the first patient enrollment and dosing in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.
It was the company s latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed company s stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalization soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($850 million) on March 1. ....

United States , Hong Kong , Brian Thevenot , Michele Gershberg , Alexandre Cavalcanti , Ricardo Zimerman , Gabriel Stargardter , Carlos Wambier , Lucy Lu , Zeid Kayali , Jair Bolsonaro , Stephen Ostroff , International In Hong Kong , Sao Paulo Hcor Research Institute , Drug Administration , Kintor Pharmaceutical , Brazilian Health Ministry , Brazil Health Ministry , Brown University , Kintor Pharmaceutical Limited , Hong Kong Listed , Sao Paulo , Research Institute , Chief Executive Tong Youzhi , China Renaissance , President Jair ,

INSIGHT-The man behind Brazil's search for miracle COVID-19 cures


11 Min Read
RIO DE JANEIRO, May 14 (Reuters) - Brazilian President Jair Bolsonaro, addressing the nation last month in a social media video, touted the latest in a string of unconventional drugs he says can ease the country’s COVID-19 crisis.
Bolsonaro - a vaccine skeptic and promoter of discredited treatments such as hydroxychloroquine - said this new drug, Proxalutamide, would “soon be available to all Brazil.” He invited a little-known Health Ministry official, Helio Angotti, to expand on its promise.
Angotti, an eye doctor with no epidemiological experience, cited a domestic Proxalutamide study showing a 92% decrease in mortality risk among hospitalized COVID-19 patients. It was a dramatic claim amid a global struggle to find effective treatments. He said he aimed to “get it to the Brazilian population as soon as possible.” ....

Sao Paulo , Estado De Pernambuco , United States , Brian Thevenot , Fiocruz Amaz , Adriano Massuda , Alexandre Cavalcanti , Ricardo Zimerman , Gabriel Stargardter , Carlos Wambier , Felipe Naveca , Jair Bolsonaro , Thomson Reuters Trust Principles , Sao Paulo Hcor Research Institute , Health Ministry , University Of Pernambuco , Health Ministry Science , Brown University , Brazil Federal Council Of Medicine , President Jair Bolsonaro , Helio Angotti , Research Institute , New England Journal , Brazilian Proxalutamide , Strategic Inputs , Like Bolsonaro ,